Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202
Senti Bio delivers exciting initial Phase 1 data for SENTI-202, with 2 of 3 Acute…
Continue ReadingSenti Bio delivers exciting initial Phase 1 data for SENTI-202, with 2 of 3 Acute…
Continue ReadingThe collaboration focuses on offering guidance, mentorship, and access to expertise to the start-ups housed…
Continue ReadingNSG BioLabs and Eppendorf Group partner to support biotech companies in Singapore
Continue ReadingFresh funding will be used to augment NSG BioLabs' infrastructure, services, and benefits for residents,…
Continue ReadingThe funds will go towards new facilities and co-working sites, likely around the Biopolis and…
Continue ReadingVerImmune wants to offer new treatment possibilities for patients facing limited options or resistance to…
Continue ReadingDespite its short history, Albatroz has been awarded a number of accolades, including the inaugural…
Continue ReadingShared lab spaces provide a streamlined launchpad, offering benches as well as a diverse network…
Continue ReadingLeading global biotechnology company Amgen and NSG BioLabs, Singapore’s largest and leading provider of biotechnology…
Continue ReadingNSG BioLabs is launching a new program to accelerate innovation in healthcare, empowering startups through…
Continue Reading